Citadel Advisors’s Spruce Biosciences SPRB Stock Holding History
Bought
Maintained
Sold
Other funds holding SPRB
ACM
Citadel Advisors's SPRB Position: Q3 2026 in Review
Citadel Advisors increased its Spruce Biosciences (SPRB) stake by 75% in Q3 2026, buying an estimated $1.96M and bringing the position to 90,610 shares worth $4.4M. The position accounts for ﹤0.01% of the portfolio, ranked #5075.
Citadel Advisors first reported a position in SPRB in Q4 2020 and has held it in 20 quarters since. The position peaked at $41.4M in Q4 2020. 70 funds tracked by Wall St. Rank hold SPRB as of Q3 2026.
- Citadel Advisors held 90,610 shares of Spruce Biosciences worth $4.4M as of Q3 2026.
- Citadel Advisors bought 38,705 Spruce Biosciences shares in Q3 2026, an estimated $1.96M.
- Spruce Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #5075 holding.
- Citadel Advisors first reported a position in Spruce Biosciences in Q4 2020 and has held it in 20 quarters since.
- Citadel Advisors's Spruce Biosciences position peaked at $41.4M in Q4 2020.
- 70 funds tracked by Wall St. Rank held Spruce Biosciences as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.